Date: 2014-10-28
Type of information: Development agreement
Compound: undisclosed drug delivery system
Company: CSL Behring (Australia) Enable Injections (USA - OH)
Therapeutic area: Rare diseases
Type agreement: development
Action mechanism:
Disease:
Details: * On October 28, 2014, CSL Behring announced that its affiliate company, CSL Behring AG, of Bern, Switzerland and Enable Injections, LLC, of Franklin, Ohio have signed a long-term development agreement for a new and innovative drug delivery system intended to improve the comfort, convenience and treatment compliance for patients with rare and serious diseases. As part of the strategic global collaboration, Enable will develop, manufacture and sell its innovative treatment administration device, which was specifically designed for subcutaneous dosing, to CSL Behring for use with one of its products on an exclusive worldwide basis. CSL Behring has the option to add subsequent additional products and extend the term of the agreement for additional periods. CSL Behring and Enable have also agreed to discuss other potential subcutaneous product partnerships. royalty payments are also called for throughout the course of the agreement. Further terms of the agreement were not disclosed.
Financial terms: Under the terms of the agreement, Enable will receive an upfront payment, as well as specific milestone payments over the next several years. Additional
Latest news:
